Mile High Labs Submits Type II DMF for CBD Isolate to U.S. FDA
Mile High Labs Expands Pharmaceutical Efforts with FDA Filing
Mile High Labs, noted for its strong footing in the cannabis industry, has recently made headlines by filing a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). This significant step reflects the company’s commitment to expanding its capabilities within the pharmaceutical sector and offering high-quality hemp-derived products. The filing pertains specifically to a 98% CBD isolate, a product that has garnered substantial interest among formulators and drug developers.
What is a Type II Drug Master File?
The Type II DMF allows companies developing drug products to reference the filed details in their own submissions to the FDA, facilitating smoother regulatory approval processes. By acquiring a Letter of Authorization from Mile High Labs, other businesses can reference DMF #044151, aiding their own product approval strategies. John Davis, the Chief Operating Officer, described this filing as emblematic of the company’s operations, highlighting their focus on quality as they navigate the challenges of a maturing cannabis industry.
The filing, submitted on October 2, 2026, signals a deepening commitment to quality which has been the compass driving Mile High Labs over the last decade. As the market for cannabinoids matures, the need for regulated, high-quality products like CBD isolates has surged. The significance of this Type II DMF extends beyond mere compliance—it marks a vital step in the evolution of Mile High Labs within increasingly regulated markets worldwide.
Future Prospects and Inspections
Mile High Labs is actively preparing for FDA inspections, aiming to bolster its reputation and operational readiness to serve drug developers both domestically and internationally. The company already has established a unified quality system that supplies various consumer and medicinal products. Such preparations not only enhance Mile High Labs’ standing but also position it competitively within the pharmaceutical landscape, which increasingly values stringent quality management and regulatory readiness.
The latest updates indicate that the new DMF is set to appear in the FDA’s public list in their following quarterly update, further establishing transparency and commitment to compliance with regulatory standards. For stakeholders, this inclusion serves as an assurance of the product’s integrity and Mile High Labs’ regulatory diligence.
About Mile High Labs
Founded over ten years ago and based in Loveland, Colorado, Mile High Labs specializes in high-quality hemp-derived cannabinoid ingredients. The firm has built a diverse portfolio that includes not only CBD but also CBG, CBN, and CBC isolates, as well as distillates and water-soluble formats. This range of products serves brands and formulators across various regulated markets in regions like the United States, the United Kingdom, the European Union, and Japan.
As Mile High Labs continues to push boundaries in cannabinoid product development and regulatory compliance, the firm remains at the forefront of a rapidly evolving industry. Their efforts to streamline quality and adhere to stringent regulations pave the way for a future where hemp-derived products play an even more central role in health and wellness applications.